A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours. - Wikidata - wikimedia - TriplyDB

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.

http://www.wikidata.org/entity/Q34250125

about

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.The potential of sunitinib as a therapy in ovarian cancer.Drug interactions with sunitinib.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.

P2860

Q26747666-193A6DF2-3CB0-455E-A19A-54396A5FC7EE Q33395853-0D8FC50F-E902-4402-AF32-DD2F8E5FBC2A Q33581969-654B1376-57DD-4E48-B9B8-22EB02A092BA Q38144166-9FBE32BF-3B11-4404-BB35-4D848A87F2E3 Q38176853-C56A514D-D004-4B62-B609-523EA2C3428A Q43841175-F5941C54-67D6-4C0A-9196-6B393AD2D356 Q47957959-295428EC-AB02-4F7D-BE01-E418CBD0329A Q52362144-6CB6FD3C-7B79-420F-AB05-584B09291916

P2860

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.

http://www.wikidata.org/entity/Q34250125

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A phase I, dose-finding study ...... s with advanced solid tumours.

@ast

A phase I, dose-finding study ...... s with advanced solid tumours.

@en

A phase I, dose-finding study ...... s with advanced solid tumours.

@nl

type

label

A phase I, dose-finding study ...... s with advanced solid tumours.

@ast

A phase I, dose-finding study ...... s with advanced solid tumours.

@en

A phase I, dose-finding study ...... s with advanced solid tumours.

@nl

prefLabel

A phase I, dose-finding study ...... s with advanced solid tumours.

@ast

A phase I, dose-finding study ...... s with advanced solid tumours.

@en

A phase I, dose-finding study ...... s with advanced solid tumours.

@nl

P1433

Q34250125-328A50EB-C67F-4C6E-A058-3EB19CBF3B66

P1476

Q34250125-80683311-DA7F-4FD1-B8FB-488369313334

P2093

Q34250125-1A2A5F57-3C21-4ABF-8FCE-846D774D284F

Q34250125-52F92D67-7CDF-4B28-A58B-8B93021B5DA4

Q34250125-5E08A2A4-971A-40D0-8724-3D05A365D163

Q34250125-61F0B60A-38BD-45F6-B622-981E92D1B38A

Q34250125-71ABF117-AD67-4C0C-A017-3E64AD068694

Q34250125-877D74DC-5686-40C9-BCB1-7F3769D06633

Q34250125-D300CD65-1FF4-4466-9429-6D7AA8D50279

Q34250125-DD5F56BA-5BA7-4DDC-8DCD-435A45992039

P2860

Q34250125-094F6CA7-DA12-4EFD-97E1-C0277B927E0F

Q34250125-0ACB191E-8CAA-4DD5-BB52-BA38456B8613

Q34250125-203B64E1-1283-4112-B9D1-F0150D357D4A

Q34250125-2155CAE3-D3CB-4B71-98B3-0FD02456F5C1

Q34250125-247A1A06-E4DF-40DF-86F2-944AB66ADA59

Q34250125-26C2C68F-F7E0-4F69-A7D0-0230A9350304

Q34250125-2C97E374-DE10-4460-8EEF-2F436EA23D62

Q34250125-2D10C6B9-BF50-46E1-8458-CCA0D2E05B48

Q34250125-3306A3A4-FA1D-42C4-9796-EE568A0F5281

Q34250125-3640AFA3-B177-4A20-BB1B-43311169FA8A

P2888

Q34250125-466E81D6-A751-4EDC-902D-DBE8DA2ED3B7

P304

Q34250125-A40802B0-04F8-4FDC-9DDB-3DF5406797C4

P31

Q34250125-EDDF26DB-203C-4AF8-B049-E69E77B27ACB

P356

Q34250125-1278C9BD-3883-462C-8452-5D0C42261E81

P407

Q34250125-473ED519-FE1C-4247-8EC6-B947CEB95D86

P433

Q34250125-D1F9105A-939F-46EA-B758-05A72C4D291B

P478

Q34250125-25C751A1-71DF-45C0-8A18-B4DA1E083D00

P50

Q34250125-6FF592CA-2CAF-4946-B82A-BEDE7B1D1AB0

P577

Q34250125-71F5E326-0769-49FB-883F-38004F7CE151

P5875

Q34250125-4153D823-7C7D-4211-8767-28DD314B881B

P6179

Q34250125-B09316FC-C2CA-451F-8999-363CE18087EC

P698

Q34250125-6B0FED9F-E1B7-4E1A-9F9D-7A02B9446732

P932

Q34250125-9860B793-8483-4463-9893-BBA5C1620627

P356

P1433

British Journal of Cancer

P1476

A phase I, dose-finding study ...... s with advanced solid tumours.

@en

P2093

A M Countouriotis

http://www.w3.org/2001/XMLSchema#string

A Ruiz-Garcia

http://www.w3.org/2001/XMLSchema#string

C Massard

http://www.w3.org/2001/XMLSchema#string

C Tillier

http://www.w3.org/2001/XMLSchema#string

E Boven

http://www.w3.org/2001/XMLSchema#string

J P Armand

http://www.w3.org/2001/XMLSchema#string

N M Brega

http://www.w3.org/2001/XMLSchema#string

V Hartog

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.

Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.

Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.

P2888

P304

993-1000

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605852

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Charles Soria

P577

2010-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45695139

http://www.w3.org/2001/XMLSchema#string

P6179

1027186934

http://www.w3.org/2001/XMLSchema#string

P698

20717111

http://www.w3.org/2001/XMLSchema#string

P932

2965864

http://www.w3.org/2001/XMLSchema#string